<DOC>
	<DOCNO>NCT02400905</DOCNO>
	<brief_summary>To demonstrate BioMimics 3D Stent System meet performance goal define VIVA Physicians , Inc. safety effectiveness Nitinol stent use treatment symptomatic disease femoropopliteal artery . It prospective , single-arm , multicenter clinical trial .</brief_summary>
	<brief_title>Evaluation Safety Effectiveness BioMimics 3D Stent System</brief_title>
	<detailed_description>The BioMimics 3D stent intend improve luminal diameter treatment symptomatic de-novo , obstructive occlusive lesion native femoropopliteal artery reference vessel diameter range 4.0 - 6.0 mm . Subjects symptomatic atherosclerotic disease femoropopliteal artery comply study eligibility criterion may consider enrollment .</detailed_description>
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Peripheral Vascular Diseases</mesh_term>
	<criteria>Symptomatic peripheral arterial disease ( PAD ) low extremity require intervention relieve de novo obstruction occlusion native femoropopliteal artery . PAD classify Rutherford clinical category 2 , 3 4 . Resting anklebrachial index ( ABI ) ≤0.90 ( ≤0.75 exercise target limb ) angiographic DUS evidence &gt; /= 60 % . Single multiple stenotic occlusive lesion within native femoropopliteal artery ( `` target lesion '' ) cross guidewire fully dilate . Single multiple target lesion must cover single stent two overlap stent . Target lesion ( ) eligible treatment least 1 cm distal origin deep femoral artery least 3 cm bottom femur . Target lesion ( ) reference vessel diameter 4.0 mm 6.0 mm . Single multiple target lesion measure ≥40 mm ≤140 mm overall length , ≥60 % diameter stenosis operator 's visual estimate . Patent popliteal artery ( stenosis ≥50 % ) distal treat segment . At least one patent infrapopliteal vessel ( &lt; 50 % stenosis ) runoff ankle . Iliac stent target limb require reintervention within 12 month prior index . Target vessel treat bypass surgery . PAD classify Rutherford clinical category 0 , 1 , 5 6 . Known coagulopathy bleeding diatheses , thrombocytopenia platelet count le 100,000/microliter INR &gt; 1.8 . Stroke diagnosis within 3 month prior enrollment . History unstable angina myocardial infarction within 60 day prior enrollment . Thrombolysis within 72 hour prior index procedure . Acute chronic renal disease ( e.g. , measure serum creatinine &gt; 2.5 mg/dL &gt; 220 umol/L ) , peritoneal hemodialysis . Significant disease obstruction ( ≥50 % ) inflow tract successfully treat time index procedure ( success measure ≤30 % residual stenosis , without complication ) . No patent ( ≥50 % stenosis ) outflow vessel provide runoff ankle . Target lesion ( ) require percutaneous interventional treatment , beyond standard balloon angioplasty alone , prior placement study stent .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>PAD</keyword>
	<keyword>PVD</keyword>
	<keyword>SFA stent</keyword>
</DOC>